• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by IVERIC bio Inc.

    7/21/23 8:30:11 AM ET
    $ISEE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ISEE alert in real time by email
    15-12G 1 tm2321665d1_1512g.htm 15-12G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549  

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Commission File Number: 001-36080

     

    IVERIC bio, Inc.

    (Exact name of registrant as specified in its charter)

     

    8 Sylvan Way
    Parsippany, NJ 07054

    (609) 474-6755

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) x
    Rule 12g-4(a)(2) ¨
    Rule 12h-3(b)(1)(i) x
    Rule 12h-3(b)(1)(ii) ¨
    Rule 15d-6 ¨
    Rule 15d-22(b) ¨

     

    Approximate number of holders of record as of the certification or notice date: One (1)

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, IVERIC bio, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: July 21, 2023 By:   /s/ Mark Reisenauer
      Name: Mark Reisenauer
      Title: President, Secretary and Treasurer

     

     

     

     

    Get the next $ISEE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISEE

    DatePrice TargetRatingAnalyst
    5/1/2023Buy → Neutral
    Guggenheim
    11/10/2022$30.00 → $20.00Buy → Hold
    Jefferies
    10/17/2022Sell → Neutral
    B. Riley Securities
    9/6/2022$12.00 → $8.00Neutral → Sell
    B. Riley Securities
    8/2/2022$20.00Buy
    UBS
    6/8/2022$30.00Buy
    Guggenheim
    6/8/2022$18.00Buy
    BofA Securities
    5/12/2022$12.00Neutral
    B. Riley Securities
    More analyst ratings

    $ISEE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Astellas Completes Acquisition of Iveric Bio

      TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t

      7/11/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on July 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 124,860 restricted stock units for shares of the Company's common stock. The restric

      7/5/23 4:05:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 15,745 restricted stock units for shares of the Company's common stock. The restr

      6/2/23 4:52:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IVERIC bio downgraded by Guggenheim

      Guggenheim downgraded IVERIC bio from Buy to Neutral

      5/1/23 7:21:51 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio downgraded by Jefferies with a new price target

      Jefferies downgraded IVERIC bio from Buy to Hold and set a new price target of $20.00 from $30.00 previously

      11/10/22 6:43:18 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio upgraded by B. Riley Securities

      B. Riley Securities upgraded IVERIC bio from Sell to Neutral

      10/17/22 1:19:22 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Leadership Updates

    Live Leadership Updates

    See more
    • Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer

      – Highly-Recognized Operational Executive and Strategic Advisor to Biotechnology Companies with a Proven Track Record – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021. Mr. Gibney is an experienced biotechnology executive and former investment banker. Mr. Gibney brings over 25 years of experience dedicated to advising biotechnology companies in the U.S. and Europe on corporate matters such as business strategy, collaboration transactions, financings, and mergers and acquisitions. As a biotechnology executive, Mr. Gibney completed multiple strategic transactions, an

      12/13/21 5:08:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Appoints Christopher Simms as Chief Commercial Officer

      – Former U.S. Franchise Head of Ophthalmics at Novartis Brings a Proven Track Record in Major Retinal Product Launches – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he successfully managed commercial operations for the U.S. Ophthalmics Franchise, launching BEOUV® (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis® (ranibizumab in

      7/19/21 7:30:00 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021, the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees. These grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan, were approved by the Company’s compensation committee pursuant to a delegation by the Company’s board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock options h

      1/5/21 8:00:00 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IZERVAY issued to IVERIC BIO, INC.

      Submission status for IVERIC BIO, INC.'s drug IZERVAY (ORIG-1) with active ingredient AVACINCAPTAD PEGOL has changed to 'Approval' on 08/04/2023. Application Category: NDA, Application Number: 217225, Application Classification: Type 1 - New Molecular Entity

      8/9/23 8:37:19 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Financials

    Live finance-specific insights

    See more
    • Astellas Completes Acquisition of Iveric Bio

      TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t

      7/11/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Enters into Definitive Agreement to Acquire Iveric Bio

      -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement un

      4/30/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

      -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio"))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a w

      4/30/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/24 8:49:05 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/23 2:33:06 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/23 1:10:29 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    SEC Filings

    See more
    • SEC Form 15-12G filed by IVERIC bio Inc.

      15-12G - IVERIC bio, Inc. (0001410939) (Filer)

      7/21/23 8:30:11 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by IVERIC bio Inc.

      EFFECT - IVERIC bio, Inc. (0001410939) (Filer)

      7/18/23 12:15:15 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by IVERIC bio Inc.

      25-NSE - IVERIC bio, Inc. (0001410939) (Subject)

      7/11/23 10:24:16 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Blumenkranz Mark S.

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:02:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Carroll David Francis

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:01:28 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Miller Christine Ann

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:00:53 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care